Cascade Chemistry begins $14m manufacturing facility expansion

pharmafile | February 19, 2021 | News story | Medical Communications Cascade Chemistry, manufacturing 

Cascade Chemistry, a leading pharmaceutical contract development and manufacturing organisation, has initiated the $14 million construction of new facilities to increase the company’s capacity to manufacture APIs (active pharmaceutical ingredients) under cGMP (current Good Manufacturing Practices standards and procedures).

The company’s new facilities, expected to be operational in the first quarter of next year, will ultimately increase the company’s floor space almost three-fold, and significantly add to its cGMP manufacturing capacity and scale. The expansion also includes 2,200 square feet of new analytical labs, a robust quality system, and additional office space.

The 28,000-square-foot building currently under construction will initially include five suites for Phase I and Phase II cGMP manufacturing, with flow hydrogenation and reactors up to 400 litres. Additional capacity for API Phase III and commercial scale cGMP manufacturing up to 1,000 litres will be added in 2022, while a second building of 7,000 square feet is reserved for future expansion.

Dr Jeremiah Marsden, President of Cascade Chemistry, said: “This $14 million expansion reflects our growing success as a reliable, experienced, and flexible outsourcing partner with exceptional chemistry problem-solving expertise.

“Our customers are increasingly requesting our assistance in producing APIs for their clinical trials, and demand has outstripped our cGMP manufacturing capacity. We were fortunate to acquire two suitable buildings just 10 minutes from our current facility, and construction of new cGMP manufacturing suites that will greatly increase our clinical trial API production capacity is now underway.”

Dr Marsden added: “We ultimately will expand into the second new building to build further cGMP capacity for commercial-stage low-volume, high-value pharmaceuticals. We are grateful for the support from our customers that is driving this expansion, as well as our employees’ dedication to excellence and their creativity and hard work that make it all possible.”

Darcy Jimenez

Related Content

Touchlight completes expansion of one of world’s largest DNA manufacturing facilities in London

Touchlight, a company that focuses on pioneering enzymatic DNA production, has announced that it has …


Takeda collaboration to optimise biopharmaceutical manufacturing announced

A 36-month joint project between Takeda’s manufacturing site in Vienna, the Research Center Pharmaceutical Engineering …

BD unveils plan for €165 million Spanish manufacturing plant

BD has announced plans to build a new €160 million manufacturing plant in Zaragoza, located …

Latest content